A Phase 1, Open Label, Single-Dose Safety, Pharmacokinetic, and Tolerability Study of Zecuity® in Adolescent Subjects With a History of Acute Migraine
Phase of Trial: Phase I
Latest Information Update: 14 Jun 2018
Price : $35 *
At a glance
- Drugs Sumatriptan (Primary)
- Indications Migraine
- Focus Adverse reactions; Pharmacokinetics
- Sponsors NuPathe
- 16 Feb 2016 Status changed from recruiting to completed as per ClinicalTrials.gov record.
- 24 Sep 2013 New trial record
- 23 Sep 2013 Dosing has been initiated, according to a NuPathe media release. Results of this study are expected in July 2014.